Fasenra (benralizumab) provides meaningful benefits for people with eosinophilic granulomatosis with polyangiitis (EGPA), including those testing positive for self-reactive antibodies called ANCAs, according to a systematic review of real-world data. Specifically, Fasenra was associated with sustained remission rates, significant corticosteroid-sparing effects, and reductions in symptoms related to the respiratory…
People with ANCA-associated vasculitis (AAV) are at a higher risk of developing certain types of cancer, particularly bladder, blood, kidney, and skin cancers, according to a meta-analysis of published studies. Men with AAV had a significantly elevated risk — 2.1 times higher — while no such increase was observed in…
Adding Tavneos (avacopan) to standard treatment is as safe and effective in older people with ANCA-associated vasculitis (AAV) as it is among younger patients, according to the findings of a post-hoc analysis of clinical trial data. The approved oral therapy “showed similar efficacy and safety results in patients…
A higher risk of death among AAV patients with interstitial lung disease (ILD) is significantly associated with older age, episodes of sudden symptom worsening, and microscopic polyangiitis (MPA), a common type of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). That’s according to a review of published studies that also pointed…
Long-term treatment with Nucala (mepolizumab) reduces disease activity and helps to prevent progressive organ damage in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), data from a real-world study show. Finding among patients in Spain also showed that most using Nucala were able…
Plasma exchange added to standard immunosuppressive treatments helps improve early kidney function in people with ANCA-associated vasculitis (AAV) who have glomerulonephritis, an inflammation of the kidneys’ filtering units, reducing the risk of kidney failure within the first year. That’s according to a new analysis of data from the…
High blood levels of the syndecan-1 protein, known to promote the survival of antibody-producing B cells, may help identify ANCA-associated vasculitis (AAV) patients with high disease activity — and those at risk of a poor prognosis — a new study suggests. The researchers defined two cut-off values of syndecan-1…
Using data from the largest ANCA-associated vasculitis (AAV) patient database compiled to date, researchers identified five new subgroups that predict patient outcomes better than classifying patients according to granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two AAV subtypes. The new disease clusters, identified with advanced artificial intelligence (AI)…
Treatment with the asthma medication montelukast may trigger eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), a case-based review study suggests. The study, “Eosinophilic granulomatosis with polyangiitis and its association with montelukast: a case-based review,” was published in Clinical Rheumatology. AAV is a…
Melodia Therapeutics has acquired the exclusive rights to develop, manufacture, and commercialize MDI-0151, a candidate therapy for hard-to-treat ANCA-associated vasculitis (AAV) and other disorders marked by overactivation of neutrophils, a type of immune cell. Melodia said it will “rapidly initiate” investigational new drug (IND)-enabling studies in preparation of a…
Get regular updates to your inbox.
